Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of SAR444336 in Healthy Adults
NCT05876767Phase 1Completed
- Sponsor
- Sanofi
- Start
- Oct 2021
- Primary completion
- Dec 2023
- Modality
- PEGylated Peptides, Interleukins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in autoimmune diseases comparing SAR444336 with Placebo (2 arms). Primary endpoint: Treatment-emergent adverse events at Day 85. Started Oct 2021; status: completed.
02
Drugs
SAR444336
03
Conditions
autoimmune diseases
Beyond the preview
Go deeper on NCT05876767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05876767.